Second Sight Medical Products secured it pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share.
Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients.
Its current product, the Argus II System, which treats outer retinal degenerations such as retinitis pigmentosa, is the only retinal prosthesis approved in the United States by the FDA and the first approved retinal prosthesis in the world.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends